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Abstract 
Angiotensin-converting enzyme (ACE) is best known for its formation of the vasopressor 
angiotensin II that controls blood pressure but is also involved in other physiological functions 
through the hydrolysis of a variety of peptide substrates. The enzyme contains two catalytic 
domains (nACE and cACE) that have different affinities for ACE substrates and inhibitors. We 
investigated whether nACE inhibitor backbones contain a unique property which allows them 
to take advantage of the hinging of nACE. Kinetic analysis showed that mutation of unique 
nACE residues in both the S2 pocket and around the prime subsites (S′) to their C-domain 
counterparts each resulted in a decrease in affinity of nACE specific inhibitors (SG6, 33RE and 
ketoACE-13), but it required the combined S2_S′ mutant to abrogate nACE-selectivity. 
However, this was not observed with the non-domain-selective inhibitors enalaprilat and 
omapatrilat. High resolution structures were determined for the minimally glycosylated nACE 
with the combined S2_S′ mutations in complex with the ACE inhibitors 33RE (1.8 Å), 
omapatrilat (1.8 Å) and SG6 (1.7 Å). These confirmed that the affinities of the nACE-selective 
SG6, 33RE and ketoACE-13 are not only affected by direct interactions with the immediate 
environment of the binding site, but also by more distal residues. This study provides evidence 
for a more general mechanism of ACE inhibition involving synergistic effects of not only the 
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S2, S1′ and S2′ subsites, but also residues involved in the subdomain interface that effect the 
unique ways in which the two domains stabilise active site loops to favour inhibitor binding. 
 
Introduction 
Angiotensin converting enzyme (ACE, EC 3.4.15.1) is a zinc metalloprotease which has 
traditionally been known for its role in blood pressure regulation via the renin-angiotensin 
aldosterone system (RAAS). During the last 20 years there has been an increasing interest in 
the function of ACE in other biological systems. The somatic form of ACE (sACE) is expressed 
on the surface of endothelial, epithelial, neuroepithelial and immune cells [1] as a type I 
transmembrane protein. Although formed from a single polypeptide chain, this protein has two 
catalytically active extracellular domains, the N- and C-domain (nACE and cACE 
respectively), which are separated by a short linker region. The high degree of homology 
between the sACE domains (60% overall sequence similarity and 89% active site identity) [2] 
suggests that they originated by an evolutionary gene duplication event and were conserved 
due to differences in their physiological function. sACE cleaves a remarkable range of 
substrates through both endo- and exopeptidase action. These include angiotensin I, 
enkephalins, kinins, neurotensin, formyl-Met-Leu-Phe, substance P[3], gonadotropin-releasing 
hormone (GnRH), also known as luteinizing hormone-releasing hormone (LH-RH) [4], N-
acetyl-Ser-Asp-Lys-Pro (AcSDKP) [5] as well as the amyloid beta-peptide (Aβ) [6, 7]. cACE 
is primarily responsible for blood pressure regulation via angiotensin I cleavage [8, 9] whereas 
the peptides GnRH, AcSDKP and Aβ are preferentially cleaved by nACE [5-7, 10, 11] and 
bradykinin is hydrolyzed by both domains [11]. 
Apart from decreasing blood pressure, the clinical use of non-domain-selective ACE 
inhibitors has been associated with various antifibrotic effects. Since this is largely attributed 
to accumulation of the ubiquitously expressed AcSDKP, selective N-domain inhibition holds 
potential for the treatment of fibrosis without affecting blood pressure [12, 13].  
ACE has also been implicated in the immune response and recently overexpression of 
ACE in macrophages and neutrophils was shown to cause an increase in oxidative metabolism 
and cellular ATP; however, the peptide substrate is currently unknown [14, 15]. Further 
highlighting the importance of controlled domain-specific ACE inhibition this link to the 
immune response is due to cACE activity [16]. 
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At present, there are only a handful of ACE inhibitors with substantial N-selectivity, of 
which the phosphinic peptidomimetic compounds RXP407 [17] and its analogue 33RE [18] 
show the most promise. Peptidic inhibitors are, however, generally considered poor drug 
candidates because of their low oral bioavailability, poor solubility and susceptibility to 
degradation by proteases [19]. Functional groups essential for N-selectivity therefore need to 
be identified to enable the design of clinically suitable nACE inhibitors. RXP407 has N-
terminal acetylated aspartate (P2), L-pseudophenylalanine (P1), L-pseudoalanine (P1ʹ) and C-
terminal amidated alanine (P2ʹ) moieties that respectively bind to the S2, S1, S1ʹ and S2ʹ subsites 
of the ACE active site (Figure 1). Its fragment-based design analogue 33RE is identical in 
structure apart from the P2 moiety being replaced by an aminomethyl tetrazole. Mutagenesis 
studies showed that the three orders of magnitude N-selectivity of these two compounds largely 
depends on interactions with unique nACE residues of the S2 subsite [18, 20]. However, unique 
prime subsite residues distal to the inhibitor binding site were also required to fully account for 
the selectivity of these compounds. Each ellipsoid domain of ACE is divided into two 
subdomains flanking the active site cleft. Previous normal-mode analysis and isothermal 
titration calorimetry studies have suggested that ligand binding is mediated by hinging and 
subsequent opening or closing of the active site cleft [21, 22]. It was recently shown via 
molecular dynamics simulations that the mechanism of hinging differs between wild-type 
nACE and a mutant where 8 unique active site residues were replaced by their cACE 
counterparts [23]. Differential scanning fluorimetry further showed that these residues were 
crucial for thermal stabilization of the protein upon 33RE binding. These nACE residues from 
the S2 subsite (Y369 and R381), the S1ʹ subsite (T358) and distal prime region (S260, E262, 
D354, S357 and E431), referred to as S2 (YR) and S′ (S1ʹ and distal prime), synergistically 
control the selectivity of 33RE and their mutation to cACE counterparts (F391, E403, V380, 
T282, S284, E376, V379 and D453, respectively) completely abolished selectivity. The only 
unique direct interaction was between the P2 tetrazole of 33RE and Y369. The unique distal 
prime residues indirectly facilitated 33RE binding by favouring the protein’s hinging towards 
active site cleft closure. In nACE, these residues formed an attractive polar subdomain interface 
whereas in cACE, this interface was hydrophobic and caused repulsion between the 
subdomains.  
Previous attempts at designing more drug-like ACE inhibitors with this mechanism of 
action have had limited success. Although addition of an aspartate moiety in the P2 position of 
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a relatively non-selective ACE inhibitor backbone such as ketoACE to produce ketoACE-13 
[24] or enalaprilat to produce SG6 (also known as compound 16) [25] increased the level of N-
selectivity, it was still far inferior to that of 33RE. It is important to understand the reason 
behind this to ensure future success in the design of highly N-selective inhibitors. We therefore 
investigated whether the 33RE backbone contains a unique property which allows it to take 
advantage of this hinging behaviour of nACE by determining the mechanisms of action for a 
range of ACE inhibitors differing in their backbones and degrees of N-selectivity, namely: 
omapatrilat, enalaprilat, SG6 and ketoACE-13 (Figure 1). This included kinetic studies using 
the S2, S′ and combined S2_S′ mutated nACE (S2-nACE, S′-nACE and S2_S′-nACE 
respectively), as well as solving high resolution crystal structures of minimally glycosylated 
nACE with the combined S2_S′ mutations (N389-S2_S′-nACE) in complex with SG6, 33RE 
and omapatrilat. 
 
Materials and Methods 
Enzymes for kinetic characterization 
Truncated wild-type or mutant proteins used for kinetic characterization were fully N-
glycosylated. Wild-type N-domain (nACE), C-domain (cACE) and the S2-, S′- and S2_S′-
nACE mutants were previously created and cloned into pcDNA3.1+ (Invitrogen) for 
mammalian cell expression [23]. Chinese Hamster Ovary K1 (CHO-K1) cells stably 
overexpressing these ACE proteins were cultured and the proteins purified using lisinopril-
sepharose affinity chromatography, as previously described [26]. 
 
Ligand preparation 
The fluorogenic substrate Abz-FRK(Dnp)P-OH was a kind gift from Prof A.K. Carmona, 
Universidade Federal de São Paulo. The peptide was dissolved in 100% DMSO and the 
concentration determined by measuring the absorbance at 365nm and extinction coefficient of 
17300 M-1 cm-1. Subsequent dilutions from the 1mM stock of were made in assay buffer 
(50mM HEPES, pH 6.8, 10μM ZnCl2, 200mM NaCl). The inhibitors 33RE [18], SG6 [25] and 
ketoACE-13 [24] were synthesized previously whereas enalaprilat dihydrate and omapatrilat 
were obtained from Sigma-Aldrich. Lyophilized 33RE, SG6 and enalaprilat were dissolved in 
distilled water to yield stock concentrations of 10mM. KetoACE-13 was dissolved in 100% 
methanol to a stock concentration of 50mM, followed by dilution in deionized distilled water 
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to 10mM. Since dimerization of omapatrilat has been previously described [27], fresh 10mM 
stocks of inhibitor were prepared in DMSO directly prior to kinetic analysis. The integrity of 
omapatrilat at ambient temperature was monitored at 50µM by HPLC (Agilent 1260 Infinity 
HPLC System with a Poroshell 120 EC-C 18 column) over the time-frame of each assay, as 
previously described [27]. A 20µl injection volume was used with a 0.5ml/min flow rate with 
A: 1% ACN, 0.1% TFA; B: 95% ACN, 0.1% TFA; and 0-100% B over 10 minutes; 214nm. 
Subsequent dilutions of all inhibitors were prepared from stock solutions  in an assay 
buffer consisting of 50mM HEPES pH 6.8, 200mM NaCl and 10μM ZnCl2 
 
Kinetic characterization of substrate hydrolysis 
Binding and hydrolysis of the fluorogenic Abz-FRK(Dnp)P-OH substrate was determined as 
previously described in an assay buffer consisting of 50mM HEPES pH 6.8, 200mM NaCl and 
10µM ZnCl2 [28]. Briefly, a 50μM solution of Abz-FRK(Dnp)P-OH was prepared in assay 
buffer (50mM HEPES, pH 6.8, 10μM ZnCl2, 200mM NaCl) and variable volumes added to a 
96-well plate on ice. A constant volume of enzyme was added to all wells and the final volume 
adjusted to 300μl with buffer to give a constant amount of enzyme with a range of substrate 
concentrations. The hydrolysis of Abz-FRK(Dnp)P-OH was continuously monitored at 
excitation and emission wavelengths of 320nm and 420nm, respectively, at ambient 
temperature using a fluorescence spectrophotometer (Cary Eclipse, Varian Inc.). The amount 
of active protein was determined immediately after purification by calculating the specific 
activity. Final enzyme concentrations in these assays were 10nM for nACE and S′-nACE, and 
5nM for S2-nACE, S2_S′-nACE and cACE. Kinetic constants were calculated by analysis of 
the initial reaction velocities (at <10% substrate hydrolysis) with the Michaelis–Menten model 
in GraphPad Prism v.6.0.  
 
Kinetic characterization of inhibitor binding 
To evaluate inhibitor binding affinity, a modified Abz-FRK(Dnp)P-OH assay was used. Serial 
dilutions of an appropriate range were prepared for each inhibitor in the afore mentioned assay 
buffer. An appropriate concentration of enzyme was similarly prepared and incubated with an 
equal volume of inhibitor for 15 min at 22°C after which 20µl volumes of the reactions were 
aliquoted to a 96-well plate. The volume per well was increased to 300µl by addition of Abz-
FRK(Dnp)P-OH on ice at an appropriate concentration to allow detectable inhibition. The final 
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substrate and enzyme concentrations for these assays were as follows. For SG6 and 
omapatrilat: 4µM Abz-FRK(Dnp)P-OH with 2.6nM enzyme; for enalaprilat: 4µM Abz-
FRK(Dnp)P-OH with enzyme at 1.3nM (nACE or cACE), 0.66nM (S′-nACE or S2-nACE) or 
0.33nM (S2_S′-nACE); for ketoACE-13: 2.6nM nACE with 4µM Abz-FRK(Dnp)P-OH, 
0.7nM S′-nACE with 3µM Abz-FRK(Dnp)P-OH, 0.2nM S2-nACE with 3µM Abz-
FRK(Dnp)P-OH, 0.2nM S2_S′-nACE with 2µM Abz-FRK(Dnp)P-OH or 0.5nM cACE with 
3µM Abz-FRK(Dnp)P-OH. Control (zero inhibitor) reactions containing the appropriate 
concentration of methanol or DMSO (in the case of ketoACE-13 or omapatrilat, respectively) 
were included to correct for any possible vehicle-induced effects on the reaction rate.  
Initial reaction velocities were analysed in GraphPad Prism v.6.0 using the Morrison 
equation (Y=(1-((((Et+X+(Ki
app))-(((Et+X+(Ki
app))^2)-4*Et*X)^0.5))/(2*Et))), where Y is 
Vi/Vo, X is the final inhibitor concentration and Et is the final enzyme concentration) to obtain 
Ki
app values. Under conditions of classical inhibition where competition with substrate affected 
Ki
app (which only applied to the ketoACE-13 kinetics), the Cheng–Prusoff equation (Ki = 
Ki
app/(1+[S]/Km); where [S] is the final substrate concentration) was used to obtain Ki values 
[29]. 
 
Engineering of a minimally glycosylated active site mutant 
nACE is routinely crystallized in a minimally glycosylated form where six of the nine N-linked 
glycosylation sites have been mutated to glutamine residues. The resulting construct, N389-
nACE, only retained glycosylation at sites 3 (Asn45), 8 (Asn416) and 9 (Asn480) [30]. To 
enable crystallization of the S2_S′-nACE active site mutant, the asparagine residues at sites 1 
(Asn9), 2 (Asn25), 4 (Asn82), 5 (Asn117), 6 (Asn131) and 7 (Asn289) were converted to 
glutamine residues. Sites 1, 2, 4, 5 and 6 were situated upstream of the active site mutations 
and could therefore be removed by molecular cloning. The N3789-S2_S′-nACE construct was 
generated by performing sequential Bsu36I and EcoRI (Thermofisher Scientific TM) restriction 
enzyme digests on the fully glycosylated pcDNA3.1+ S2_S′-nACE and the minimally 
glycosylated pcDNA 3.1+ N3-nACE [31] and ligating the N-terminal region of the latter to the 
C-terminal fraction of the former, containing the active site mutations. A double digest of 
EcoRI and XbaI was performed to screen for the presence of a ~2000bp coding region and thus 
generation of the pcDNA 3.1+ N3789-S2_S′-nACE construct. Glycosylation site 7 (Asn289) 
was located amongst the active site mutations and as such was mutated to glutamine via site-
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directed mutagenesis using the Kapa HiFi PCR kit (Roche Molecular Systems Inc.) and 
previously designed primers [30]. Positive introduction of the desired mutation, and thus 
generation of the pcDNA 3.1+ N389-S2_S′-nACE construct, was confirmed by restriction 
enzyme screening for the simultaneously introduced NdeI site. Additionally, bidirectional 
nucleotide sequencing was performed to confirm the presence of all active site mutations and 
N>Q mutation of sites 1, 2, 4, 5, 6 and 7. 
 
Heterologous expression of minimally glycosylated mutant ACE 
The construct was transfected into Chinese hamster ovary (CHO-K1) cells using the calcium 
phosphate Profection® Mammalian Transfection System (Promega Corp.), heterologously 
expressed and the protein purified from culture medium via lisinopril–sepharose affinity 
chromatography, as previously described [26]. Protein purity was assessed by SDS–PAGE and 
Coomassie staining. Purified protein was quantified by absorbance with the use of a 
NanoDrop® spectrophotometer and extinction coefficient of 162 070 M−1 cm−1 for nACE. 
 
X-ray crystallographic studies 
N389-S2_S′-nACE was pre-incubated with the ligands for 1 hour at room temperature using a 
4:1 v/v ratio of 5 mg ml-1 protein (in 50 mM HEPES, pH 7.5, 0.1 mM PMSF) and inhibitor (20 
mM 33RE or SG6, 5 mM omapatrilat). Hanging drops of 1 µl of the protein-inhibitor complex 
mixed with an equal volume of reservoir solution were set up. The standard condition for nACE 
(30% PEG 550 MME/PEG 20000, 0.1 M Tris/Bicine pH 8.5, and 60 mM divalent cations, 
Molecular Dimensions Morpheus A9) was used to test for N389-S2_S′-nACE crystallisation, 
and it produced crystals of the same morphology. 
X-ray diffraction data were collected on stations i03 (33RE) and i04-1 (omapatrilat and 
SG6) at the Diamond Light Source (Didcot, UK), with the crystals kept at a constant 
temperature (100 K) using a nitrogen stream. Images were collected using PILATUS3 6M 
(33RE) and PILATUS-6M-F (omapatrilat and SG6) detectors (Dectris, Switzerland). Raw data 
images were indexed and integrated with DIALS [32], and then scaled using AIMLESS [33] 
from the CCP4 suite [34]. Initial phases were obtained by molecular replacement with 
PHASER [35] using N389-nACE PDB code 6F9V [36] as the search models. Further 
refinement was initially carried out using REFMAC5 [37] and then Phenix [38], with COOT 
[39] used for rounds of manual model building. Ligand and water molecules were added based 
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on electron density in the mFo – DFc Fourier difference map. MolProbity [40] was used to 
help validate the structures. Crystallographic data statistics are summarized in Table 3. All 
figures showing the crystal structures were generated using CCP4mg [41], and schematic 
binding interactions are displayed using Ligplot+ [42]. 
 
Results  
It is known that synergism between unique S2 subsite and subdomain interface residues is 
important for the N-selectivity of 33RE [23]. To evaluate whether this mechanism of selectivity 
is applicable to other ACE inhibitor backbones site-directed mutagenesis, enzyme kinetics and 
X-ray crystallography were employed. 
  
Kinetic characterization of substrate hydrolysis 
The truncated (single domain) wild-type N-domain (nACE), wild-type C-domain (cACE) and 
N-domain mutant constructs S2-nACE (Y369F and R381E), S′-nACE (S260T, E262S, D354E, 
S357V, T358V and E431D) and S2_S′-nACE (S260T, E262S, D354E, S357V, T358V, Y369F, 
R381E and E431D) were heterologously expressed in CHO-K1 cells [23]. The secreted 
proteins were purified to homogeneity via lisinopril-coupled sepharose affinity 
chromatography and SDS-PAGE showed single bands for each construct corresponding to 
approximately 90 kDa for nACE/mutants and 70 kDa for cACE (data not shown). Hydrolysis 
of the quenched fluorogenic substrate Abz-FRK(Dnp)P-OH was characterized and it was 
observed that the S2-nACE and S2_S′-nACE displayed lower binding affinities (Km of 11.92 
μM and 12.40 μM, respectively) and higher catalytic turnover rates (kcat of 4.5s-1 and 6.0s-1, 
respectively) compared to both wild-type domains and S′-nACE (Table 1). The overall 
efficiency of substrate hydrolysis (kcat/Km) was, however, comparable between all proteins 
studied in agreement with our previous study [23].  
 
Kinetic characterization of inhibitor binding 
Previous kinetic studies reported that 33RE was a high affinity inhibitor of nACE (Ki of 11.21 
nM) and had approximately 1000-fold selectivity over cACE [18] with S′-nACE, S2-nACE and 
S2_S′-nACE mutations respectively leading to decreases in binding affinity of 22-, 254- and 
900-fold [23] (Table 2). This shows that the S2 mutations have a greater effect than the S′ on 
33RE affinity of nACE and that upon combining all eight mutations in S2_S′-nACE, a 
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synergistic effect occurs so that the affinity for 33RE is similar to that seen for cACE (Figure 
2A). Here, we studied the effect of these mutations on the binding of two reportedly moderately 
N-selective inhibitors, SG6 and ketoACE-13, and two non-selective inhibitors, omapatrilat and 
enalaprilat. 
To enable comparison between inhibitors of different potencies, Morrison plots were 
constructed from initial reaction velocities in the presence of different inhibitor concentrations 
(Vi) as a fraction of velocity in the absence of inhibitor (V0) for the wild-type and mutant 
enzymes. Omapatrilat, enalaprilat and SG6 showed picomolar to nanomolar potency for all 
enzymes tested and exhibited a tight-binding mode of inhibition (Table 2). Since no 
competition with substrate was detected for these inhibitors it was assumed that Ki 
app 
approximates Ki, as recently described for omapatrilat [27]. KetoACE-13 displayed 
significantly lower potency (micromolar range) compared to the other inhibitors tested and a 
classical mode of inhibition. In this case, Ki 
app no longer approximated Ki and the latter were 
calculated using the Cheng-Prusoff equation where Ki = Ki 
app/(1+([S]/Km)) [29]. 
The diprolyl analogue of enalaprilat, SG6, displayed Ki values of 0.093nM and 76.77nM 
for nACE and cACE, respectively, and thus 825-fold N-selectivity similar to that of 33RE. The 
effect of mutation follows a similar trend to that of 33RE with S2 and subdomain interface 
residues synergistically controlling N-selectivity.   The S′ mutations resulted in a modest 11-
fold decrease in affinity (Ki of 1.09nM), followed by a more pronounced decrease of 474-fold 
with S2-nACE (Ki of 44.05nM) and a drastic decrease of 784-fold when all mutations were 
combined in S2_S′-nACE (Ki of 72.93nM), thereby yielding cACE-like affinity. From these 
data it can be concluded that for 33RE and SG6 some, or all, of the S′ residues play a significant 
role in their binding, although this appears to be mainly if the affinity from the direct binding 
interactions (S2 residues) has also been reduced. 
The binding affinities obtained here for ketoACE-13 (Ki values of 1000nM and 8250nM 
for nACE and cACE, respectively (Table 2)) were higher and the degree of N-selectivity 
slightly lower than those reported previously by Sharma et al. [24]. This discrepancy is partly 
due to the use of initial inhibitor concentrations as opposed to final inhibitor concentrations in 
Ki calculations by the previous authors, which meant a 4-fold increase in their values. 
Interestingly, the 8-fold N-selectivity of ketoACE-13 was markedly lower compared to that of 
33RE and SG6 determined here under identical conditions, despite the presence of a P2 
aspartate for interaction with the unique Y369 and R381 residues of the S2 subsite. 
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Nevertheless, the mutations studied here elicited the same trend of decreased binding affinity 
for ketoACE-13 as for SG6 and 33RE with synergism existing between the S2 and S′residues 
(Figure 2A). This was rather unexpected given the low degree of N-selectivity observed for 
this compound. The S′ mutations led to a 3-fold reduction in binding affinity (Ki of 2990nM) 
which, considering the low selectivity of ketoACE-13, was a drastic change towards cACE-
like inhibition. Interestingly, S2-nACE and S2_S′-nACE had even lower affinities than cACE 
for ketoACE-13 with Ki values of 17810nM and 47750nM, respectively. Since the active site 
of S2-nACE is essentially equivalent to that of cACE, some property distal to the cACE active 
site appears to minimize the effect of Y369 and R381 loss on its inhibition by ketoACE-13. 
This property is likely lacking in nACE and it therefore depends on the S2 and subdomain 
interface residues for inhibition by ketoACE-13. 
This property potentially also affects the binding of enalaprilat. This compound binds 
with a 5-fold greater affinity to cACE than nACE (Ki values of 0.75nM and 0.16nM for nACE 
and cACE, respectively), yet mutation ofS′, S2 and S2_S′ counterintuitively resulted in slightly 
decreased binding affinities (2.5-, 2- and 4-fold, respectively) compared to nACE. This 
suggests that these residues facilitate nACE inhibition even in the absence of a P2 moiety and 
that cACE relies on some factor distal to the binding site for its effective inhibition. Addition 
of a P2 aspartate, as in SG6, likely strengthens the intrinsic synergism between nACE subsites 
to bring about selectivity.  
Omapatrilat displayed sub-nanomolar potency for nACE and cACE with Ki values of 
0.37nM and 0.70nM, respectively, in line with previous reports [27]. Omapatrilat was 
evaluated via HPLC during the assay timeframe to monitor potential dimer formation. A small 
fraction of dimer (2.56%) was detected immediately after solubilization and this increased by 
a mere 0.86% after one hour at ambient temperature (Figure 2B), confirming that the monomer 
was the dominant species during kinetic characterization. Even after 3 hours of incubation at 
ambient temperature, only 11% dimer was detected. This was lower than that reported 
previously [27], suggesting that the current buffer conditions (50mM HEPES pH 6.8) are more 
suitable for future studies with omapatrilat. Interestingly, omapatrilat binding was not affected 
by any of the mutations tested (Table 2), suggesting that the effects observed for enalaprilat 
were overruled by attributes like the strong zinc-chelating sulfhydryl and carbonyl moieties or 
more favoured orientation within the active site of the former. 
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Engineering of a minimally glycosylated S2_S′-nACE 
ACE is heavily glycosylated and contains ten N-domain and seven C-domain potential N-
linked glycosylation sites of which all except one site per domain are occupied by complex-
type glycans. To enable crystallization, minimally glycosylated versions of the truncated wild-
type domains were previously engineered by Asn>Gln mutation at certain positions [30, 43]. 
The nACE mutant N389-nACE, which only retained glycosylation at sites 3 (Asn45), 8 
(Asn416) and 9 (Asn480), was catalytically active and the most amenable to crystallization. At 
present, more than 20 crystal structures have been solved of N389-nACE complexed to a 
variety of ligands. Here, we created a minimally glycosylated version of S2_S′-nACE (N389-
S2_S′-nACE) to gain structural insight into the pronounced effects that these mutations have 
on inhibitor binding. The N-linked glycosylation sites 1 (Asn9), 2 (Asn25), 4 (Asn82), 5 
(Asn117) and 6 (Asn131) were converted to glutamine residues by subcloning the N-terminus 
of S2_S′-nACE with that of N389-nACE.  Replacement of site 7 (Asn289), however, required 
the use of site-directed mutagenesis due to its location between the E262S and D354E 
mutations of the active site.  The minimally glycosylated active site mutant N389-S2_S′-nACE 
was successfully created, stably transfected, expressed and purified as illustrated by the lower 
molecular weight on SDS-PAGE compared to S2_S′-nACE (Figure 2C). 
 
Crystallisation of N389-S2_S′-nACE inhibitor complexes 
The minimally glycosylated N389-nACE readily crystallises in the presence of ligands using a 
single condition that was identified from initial screens, and no screening around this condition 
is needed even for new ligand complexes. Therefore, this condition (Morpheus A9 from 
Molecular Dimensions: 30% PEG 550 MME/PEG 20000, 0.1 M Tris/Bicine pH 8.5, and 60 
mM divalent cations) was tried for N389-S2_S′-nACE as both the native enzyme, and in 
complex with 33RE, SG6 and omapatrilat. We hypothesised that structures with these 
inhibitors would provide the most information about the S2_S′ mutations since the kinetic data 
showed that omapatrilat is entirely independent and 33RE/SG6 greatly dependent on these 
residues for binding affinity. Even after multiple attempts, and using streak seeding from other 
N389-nACE crystals, no native (without the presence of a ligand) N389-S2_S′-nACE crystals 
grew. The N389-nACE protein also rarely crystallises in the native form, and even when 
crystals do form, they always have elements from the purification and crystallization conditions 
bound in the active site.  
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However, N389-S2_S′-nACE readily crystallised in the presence of the three ligands 
(33RE, SG6 and omapatrilat). All the complexes were in the P1 space group with two 
molecules of the protein in the asymmetric unit. The structures were determined at high 
resolutions of 1.8 Å for both 33RE and omapatrilat, and 1.7 Å for SG6 (Table 3). 
 
Overall structure of the N389-S2_S′-nACE mutant 
The overall fold of N389-nACE, with the molecular replacement model PDB 6F9V being a 
typical example, has previously been shown to be a mainly α-helical ellipsoid comprising of 
two sub-domains (Figure 3A). These sub-domains form a closed structure containing a two-
lobed cavity (the Sʹ and S subsites) with the active site zinc at the junction of the two lobes. 
Contained within the first 100 residues is a flexible region that has been described as ‘lid-like’, 
and has been suggested to control peptide access into the active site [43]. This typically shows 
higher temperature factors (B-factors) than the rest of the structure and is usually poorly 
defined in one molecule of the asymmetric unit as a result of the crystal packing. The degree 
of flexibility shown does not appear to be caused by the ligand bound as it can vary from crystal 
to crystal of the same complex. 
All three of the N389-S2_S′-nACE complex structures (with 33RE, SG6 and omapatrilat 
inhibitors) show a very similar overall fold to each other and are also essentially the same as 
seen for N389-nACE (Figure 3B-D). This is reflected in the RMSD values, for 602 Cα atoms 
observed in all aligned structures, which vary from 0.34 to 0.52 Å (Table 4).  
The high resolution of the structures presented here, in particular for the SG6 complex, 
confirm the presence of the S2_S′ mutations that had been introduced (Figure 4). In all three 
N389-S2_S′-nACE complex structures (33RE, SG6 and omapatrilat) clear, unambiguous 
electron density for the bound ligands was observed in the mFo-DFc omit maps (Figure 5A-
C). This showed all the ligands bound in the S2ʹ, S1ʹ and S1 subsites, with 33RE and SG6 also 
extending into the S2 subsite. The details of the binding interactions for these ligands are 
described below. 
 
Interactions of 33RE with the N389-S2_S′-nACE binding site 
As mentioned above, 33RE is bound in the S2ʹ to S2 subsites (Figure 6A) with its amide group 
located in the typical peptide C-terminal binding site composed of hydrogen bonding from the 
amide oxygen with Gln259, Lys489 and Tyr498, and a water-mediated interaction of the amide 
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nitrogen with Lys489. The P2ʹ alanine-like residue of 33RE also forms extensive hydrophobic 
interactions with Tyr501 and His491. 
The backbone carbonyl of the P1ʹ alanine mimic has hydrophilic interactions with the 
sidechains of His331 and His491, while the backbone carbon atom (that would be equivalent 
to a peptide backbone nitrogen) has a hydrophobic interaction with His331.  
The zinc binding group of 33RE is a phosphinic acid that replaces the P1 backbone 
carbonyl of a peptide and forms a bidentate interaction with the zinc ion as well as hydrogen 
bonds with Tyr501, His361 and His365. The P1 backbone nitrogen of 33RE interacts with a 
water molecule that coordinates with Glu389, Arg500 and Tyr501. The phenylalanine-like 
sidechain hydrophobically interacts with His331, Ser333, Phe490 and Thr496.  
The P2 group of 33RE has a peptide-like backbone with the carbonyl having a hydrogen 
bond with Ala334. The 33RE P2 sidechain, a tetrazole, shows hydrophobic interactions with 
His365, and hydrogen bonds to two water molecules that are also bound by the Gly382 
backbone nitrogen, Pro385 backbone carbonyl and Glu389 sidechain. There are also three 
ethylene glycol molecules (from the crystallization buffer) that interact with the 33RE P2 group 
via the backbone nitrogen, another nitrogen from the tetrazole group and a hydrophobic 
interaction with the tetrazole carbon atom. 
 
Interactions of SG6 with the N389-S2_S′-nACE binding site 
The P2ʹ and P1ʹ groups of SG6 are essentially mimics of proline and alanine respectively. 
Therefore, it is not surprising that the P2ʹ carboxylic acid group has identical interactions with 
Gln259, Lys489, His491 and Tyr498 described above for 33RE (Figure 6B). The similarity 
continues where the prolyl ring has extensive hydrophobic interactions with Tyr501. The 
backbone carbonyl of the P1ʹ alanine residue hydrogen bonds with His331 and His491, and the 
nitrogen interacts with His331 and the backbone of Ala334.  
The P1 group of SG6 differs from a peptide by having a carboxylic acid group replacing 
the backbone carbonyl, and this forms a bidentate interaction with the active site zinc ion, as 
well as having hydrogen bonds with Tyr501 and His365. The prolyl ring sidechain of SG6 has 
hydrophobic interactions with His331, Phe490 and Thr496. 
SG6 has a P2 aspartate group where the backbone carbonyl and nitrogen form hydrogen 
bonds with the backbone nitrogen and carbonyl respectively of Ala334. The aspartate sidechain 
has hydrophobic interactions with His365, and a water mediated hydrogen bond with Glu389. 
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There is a complex structure (from the crystallisation buffer) of two bicine molecules, a calcium 
ion and water molecules that is adjacent to the SG6 P2 aspartate. The carboxylic acid group of 
the aspartate forms part of the calcium ion’s coordination sphere, as well as interacting with 
one of the bicine molecules. In addition, the backbone nitrogen of the aspartate has direct, and 
water mediated hydrogen binds with the second bicine. 
 
Interactions of omapatrilat with the N389-S2_S′-nACE binding site 
Omapatrilat contains atoms that mimic a peptide backbone, and this includes the P2ʹ carboxylic 
acid group that binds in the typical S2ʹ carboxy terminus binding site showing direct hydrogen 
bonds with Gln259, Lys489 and Tyr498, a water mediated interaction with Lys489, and 
hydrophobic interaction with His491 (Figure 6C). The P2ʹ ring of omapatrilat has hydrophobic 
interactions with Phe435 and Tyr501. 
The P1ʹ ring also shows hydrophobic interactions, these are with Val358 and His361. 
Whereas the P1ʹ backbone carbonyl mimic hydrogen bonds to His331 and His491, and the 
backbone nitrogen equivalent interacts with the backbone of Ala332.  
The P1 group of omapatrilat contains a carbonyl group that binds to the active site zinc 
ion as well as His361 and Tyr501. There is also a sulphur ion that binds to the zinc ion, and to 
His365 via a hydrophobic interaction. The P1 phenyl sidechain has hydrophobic interactions 
with Ser333, Phe490 and a bicine molecule from the crystallization buffer. 
 
Discussion 
Comparison of mutant structures with the wild-type 
The inhibitors co-crystallised with N389-S2_S′-nACE in this study have all been previously 
solved in complex with N389-nACE (33RE PDB 4BXK [18], omapatrilat PDB 6H5X [27], 
SG6 PDB 6EN5 and 6EN6 [25]). Therefore, comparisons can be directly made to see how the 
S2_S′ mutations affect the binding interactions of these ligands. 
N389-S2_S′-nACE contains mutations in the S2 subsite (Y369F and R381E, Figure 7A-
C), S1ʹ subsite (T358V, Figure 7D-F) and beyond the S2ʹ subsite (S260T, E262S, D354E, 
S357V and E431D, Figure 7G-I). Residue Thr358 may also have a longer-range effect on the 
S2ʹ subsite when there are larger P2ʹ groups such as tryptophan. As described above, these 
mutations have very little effect on the overall structure of the enzyme when ligands are bound. 
It is therefore not surprising that for all three inhibitors, the majority of interactions are 
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unchanged when comparing the N389-nACE and N389-S2_S′-nACE complexes (Figure 6). 
This is consistent with five of the eight mutations in N389-S2_S′-nACE being distant from the 
typical S2ʹ to S2 subsites. In addition, an overlay of the structures show that the ligands adopt 
almost identical conformations in the N389-nACE and N389-S2_S′-nACE structures (Figure 
5D-F), apart from a small difference in the SG6 P2 aspartate sidechain as described below. 
Comparison of the 33RE complex structures shows that all interactions with the P2ʹ to P1 
groups are conserved. The only significant difference in interactions is observed with the P2 
group of 33RE, as a result of the Y369F mutation. In the wild-type 33RE structure, the hydroxyl 
group of Tyr369 interacts with the tetrazole side chain of 33RE, and this interaction is 
obviously removed by the mutation to phenylalanine (Figures 6A, D and 7A). This is consistent 
with the reduction in affinity observed for S2-nACE compared to wild-type nACE. 
The interactions with SG6 are identical in both N389-nACE and N389-S2_S′-nACE 
except for those with the carboxylic acid group of the P2 sidechain (Figures 6B, E and 7B). In 
N389-nACE this group has a direct hydrogen bond with Tyr369 and a weak water-mediated 
interaction with Arg381 (in eight molecules of nACE from two crystal structures, the electron 
density for Arg381 was weak and showed a mixture of conformations, with not all able to form 
this interaction). These two residues are mutated to phenylalanine and glutamate, respectively, 
in N389-S2_S′-nACE and are unable to interact with the carboxylic acid group. This lack of 
interactions from the protein is likely the cause of the change in rotation of the P2 group in the 
N389-S2_S′-nACE structure compared to the N389-nACE complex (Figure 5E), and the 
subsequent binding of the calcium and bicine complex described above (Figure 6E). There is 
also an effect on the water molecules around the SG6 P2 sidechain such that in N389-S2_S′-
nACE, Arg500 is no longer involved in a water mediated interaction. This reduction in 
interactions between SG6 and the protein explains the increase in Ki of SG6 for S2-nACE 
compared to nACE. 
As with P2ʹ to P1 groups of 33RE, all the interactions with omapatrilat are conserved in 
both the N389-nACE and N389-S2_S′-nACE complex structures, although one is altered 
(Figures 6C, F and 7F). In this case there are no additional bonds, instead the hydrophobic 
interaction from the P1ʹ ring of omapatrilat with residue 358 is different because it is a threonine 
in N389-nACE, but mutated to valine in N389-S2_S′-nACE. The kinetic data showed that the 
affinity of omapatrilat for nACE is unchanged by the mutations, which is reflected by all the 
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interactions being conserved, and indicates that the T358V mutation essentially does not affect 
the strength of that hydrophobic interaction. 
 
The role of distal interactions in domain-selectivity 
Despite the similarities between the mutant and wild-type structures, the binding affinities of 
33RE, SG6, ketoACE-13 and enalaprilat were altered by mutation of the S2_S′ residues, albeit 
to different degrees. This suggests that the affinities of these ligands for nACE are not only 
affected by direct interactions and the immediate environment of the final binding site, but also 
by residues more distant. In contrast, omapatrilat was unaffected by mutation and displayed 
sub-nanomolar inhibition for the mutants as well as nACE and cACE, which raises the question 
of how these distant residues can affect binding of some ligands, but not others? 
Five of the mutated residues (Ser260, Glu262, Asp354, Ser357 and Glu431, referred to 
as SEDSE hereafter) are located at the edge of the Sʹ lobe on either side of where the two sub-
domains of nACE come together (Figure 8A) and are structurally near the hinge 2 and 4 region. 
Since this is beyond the typical S2ʹ subsite, these residues can only have a direct involvement 
in binding of ligands if there is a long P2ʹ group or if the ligand extends to what would be a S3ʹ 
subsite. The SEDSE residues therefore have no ligand interactions in the structures presented 
here (Figure 7G-I). Examination of N389-nACE structures show that there is a water-mediated 
interaction between Ser357 of subdomain 1 and Glu431 of subdomain 2, which are two of the 
SEDSE residues. In some of the structures solved to date, there are direct and water-mediated 
interactions between Asp354 of subdomain 1 and Glu262 of subdomain 2. In other structures, 
a magnesium ion has been identified that is coordinated by Asp354, Asn263 (a subdomain 2 
residue conserved in cACE) and Glu262, and 3 water molecules, one of which is coordinated 
to Ser260. Therefore, in the presence of metal ions (in this case magnesium which probably 
comes from the crystallization buffer), all the SEDSE residues are involved in interactions 
between the two subdomains. When these residues are mutated, as seen in Figure 8B, there is 
no interaction between residues 357 and 431 and, while there is still a water-mediated 
interaction between Asn263 and Glu354, overall the strength of interaction between the 
subdomains is weaker. 
Previously, it was shown that synergism between the S2 subsite residues (YR), the S1ʹ 
T358 (which has no direct interactions) and the distal prime subsite residues (SEDSE) was 
responsible for the 1000-fold N-selective binding of 33RE [23], the molecular basis of which 
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was elucidated by molecular dynamics simulations. While the interaction of Y369 with the 
tetrazole of 33RE was important to directly stabilize the molecule in the active site, R381 and 
the distal T358 and SEDSE residues were indirectly involved. R381 is located on a flexible 
loop, known as hinge region 3, between the two subdomains and propelled the tipping motion 
of the lid region via repulsion of its R90 residue to favour cleft closure. The distal prime subsite 
residues increased 33RE binding affinity by providing a hydrophobic environment for  the P1ʹ 
pseudoalanine (T358) and creating a polar subdomain interface to drive active site closure via 
hinging at the neighbouring hinge regions 2 and 4. This is consistent with the subdomain 
interactions described above for the crystal structures presented here. 
Prior to obtaining the kinetic results presented here, it was believed that 33RE was the 
only ACE inhibitor to date with this mechanism of action due to some unique properties 
contained in its backbone. Amidation of the C-terminal pseudoalanine was thought to be crucial 
in conferring selectivity based on an earlier study on the parent of 33RE, RXP407 [17], whereas 
the weaker phosphinic acid zinc binding group was thought to allow selection based on the 
inter-subsite synergism. Here we have found, however, that SG6 (which has a completely 
different backbone except for the P1ʹ pseudoalanine) follows the same mechanism of action as 
33RE. These two moieties are therefore not a requirement for N-selectivity. Although it had 
the same level of selectivity, SG6 was, however, much more potent than 33RE with picomolar 
to nanomolar affinities for all enzymes tested. This is likely due to its stronger zinc-binding 
(carboxylic acid) and/or C-terminal (proline with free carboxylic acid) moieties.  
Previous work on ketoACE analogues where P2 aspartate and P2ʹ amidated pseudoalanine 
or -proline moieties were incorporated onto this backbone had much lower N-selectivities 
compared to RXP407 [24]. The kinetic results presented here confirm these findings for 
ketoACE-13 and suggest that it is in part caused by the absence of a P1ʹ pseudoalanine. This 
group is commonly found in many ACE inhibitors and is often described as being important 
for potency, but not necessarily domain-selectivity [44]. For more ‘traditional’ ACE inhibitors 
that only consist of P1 to P2ʹ groups, addition of a P1ʹ pseudoalanine would likely increase 
binding, but not selectivity, by introducing a hydrophobic moiety in the proximity of the nACE 
residue T358 and its cACE counterpart V380. Although these residues are not in direct contact 
with the P1ʹ pseudoalanine (typically more than 4Å away), they likely create a more favourable 
environment for positioning of the inhibitor and direct interaction with the zinc and conserved 
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residues. In the case of 33RE or SG6, however, this group likely enhances the active site closure 
mediated by the SEDSE residues, thus increasing the selectivity relative to ketoACE-13.  
It was interesting to note that for ketoACE-13 and enalaprilat, but not omapatrilat, 
mutation of S2_S′ resulted in binding affinities that were respectively 6-fold and 19-fold lower 
than that of cACE. These mutations created a binding site which was essentially equal to that 
of cACE and indicates that although the direct enalaprilat interactions are conserved between 
the two domains, the mechanism of inhibition differed. To better understand this phenomenon, 
the previously published structure of enalaprilat complexed to cACE (PDB ID 1UZE)[45] was 
carefully inspected. It is proposed that effective inhibition of nACE by enalaprilat still relies 
on R381 to control lid tipping and S′ to control subdomain contact despite the absence of a P2 
group for interaction with Y369. The P2 group is likely not required for potent nACE inhibition 
when the P1ʹ pseudoalanine and acidic P2ʹ pseudoproline moieties are present, as in enalaprilat. 
Since cACE is less favoured for active site closure due to repulsion at the subdomain interface, 
but still effectively inhibited by enalaprilat, we hypothesized that some property distal to the 
active site might assist in its inhibition. The P1 pseudophenylalanine is present in ketoACE-13 
as well as enalaprilat and interacts with nACE T496 or cACE V518. Although the more 
hydrophobic valine might slightly increase the strength of the P1 interaction, it is unlikely to 
explain the discrepancy between cACE and S2_S′-nACE inhibition by enalaprilat. 
Interestingly, the T496/V518 residues are located on a long loop region that connects the helix 
harbouring nACE Y523 / cACE Y501 (which binds to the inhibitor backbone) to conserved 
residues (nACE H491, Y498 / cACE H513, Y520) which bind to the inhibitor’s prime moieties 
(Figure 9). This loop region appears to be uniquely stabilized in the cACE enalaprilat structure 
by the presence of a hydrogen bond between the residing S516 (replaced by Asn in nACE) and 
E143 (replaced by Ser in nACE) proximal to the lid region.  This interaction is only observed 
in some cACE crystal structures which suggests that it is transient, in line with the dynamic 
nature of residues around the lid region. It likely plays an indirect role during the binding 
process by driving the loop region’s dynamics towards the bent conformation observed in the 
ligand-bound state so that inhibition occurs despite the barrier to subdomain contact close to 
the cACE prime subsites. The two domains of ACE thus appear to have unique ways of 
stabilizing/guiding active site loops to favour ligand binding. Since S2_S′-nACE results in loss 
of interactions important in nACE stabilization and naturally lacks those present in cACE, the 
affinity for enalaprilat and ketoACE-13 is lower for this mutant than either wild-type domain. 
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It likely only offers an advantage to cACE if either the P2 or P1ʹ interactions are absent, as with 
enalaprilat and ketoACE-13 respectively, since this decreases the strength of nACE inter-
subsite synergism. This effect of loop stabilization was not observed for omapatrilat which 
inhibited all enzymes equally, likely due to it being overruled by strong zinc chelation. Future 
investigations into the dynamics of these distal regions might yield insight into the divergent 
substrate specificities of the highly conserved ACE active sites. 
 
Conclusion 
Typically, protein-ligand interactions are usually the focus for the design of inhibitor potency 
and specificity. In this study we show that to achieve the desired domain specificity of next-
generation ACE inhibitors, it is important to also consider intra-protein interactions and distal 
residues that the inhibitor may transiently interact with during entry into the binding site. Thus, 
the entire protein must be considered as a dynamic molecule and not just the active site in 
isolation. 
While this does add to the complexity for the design process, due to the high degree of 
similarity between the binding sites of nACE and cACE, this new information will prove 
beneficial in obtaining new domain specific inhibitors. Further study is required to fully 
understand these distal effects and this will help with inhibitor development. 
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The atomic co-ordinates and structure factors have been deposited in the RCSB Protein Data 
Bank (www.rcsb.org/pdb) with accession numbers 6TT1, 6TT3 and 6TT4. The atomic co-
ordinates and experimental data will be released upon article publication. 
 
Abbreviations 
Abz, o-aminobenzoyl; Aβ, amyloid beta-peptide; ACE, Angiotensin-1 converting enzyme; Ac-
SDKP, acetyl-Ser-Asp-Lys-Pro; CHO, Chinese hamster ovary cells; DMSO, dimethyl 
sulfoxide; Dnp, dinitrophenyl; GnRH, gonadotropin-releasing hormone; LH-RH, luteinizing 
hormone-releasing hormone; PDB, Protein Data Bank; RAAS, renin-angiotensin aldosterone 
system 
 
20 
 
Author contribution statement  
G.E.C. performed the crystallography experiments, analysed the data, wrote the draft version 
and edited the manuscript. L.L. performed the mutagenesis and kinetics study, analysed the 
data, wrote the draft version and edited the manuscript. E.D.S. supervised the mutagenesis and 
enzyme kinetics study, analysed the data and edited the manuscript. K.R.A. and E.D.S. 
conceptualized the study. K.R.A. supervised the structural study, analysed the data and edited 
the manuscript. All authors reviewed the manuscript. 
 
Acknowledgements 
We thank the scientists at stations i03 and i04 (Proposal Number mx17212) of Diamond Light 
Source, Didcot, Oxfordshire (UK), for their support during X-ray diffraction data collection. 
We are grateful to Mrs S.L.U. Schwager for purification of the fully glycosylated S2_S′-nACE 
mutant protein.  
Competing interests  
We declare that there are no conflicts of interest 
 
Funding information  
This work was supported by the Medical Research Council (U.K.) Project Grant 
MR/M026647/1 (to K.R.A.) and by a UK Global Challenge Research Fund grant: START-
Synchrotron Techniques for African Research and Technology (Science and Technology 
Facilities Council grant ST/R002754/1) (to L.L. and E.D.S.). 
 
References 
1 Bernstein, K. E., Ong, F. S., Blackwell, W. L., Shah, K. H., Giani, J. F., Gonzalez-
Villalobos, R. A., Shen, X. Z., Fuchs, S. and Touyz, R. M. (2013) A modern understanding of 
the traditional and nontraditional biological functions of angiotensin-converting enzyme. 
Pharmacol Rev. 65, 1-46 
2 Soubrier, F., Alhenc-Gelas, F., Hubert, C., Allegrini, J., John, M., Tregear, G. and 
Corvol, P. (1988) Two putative active centers in human angiotensin I-converting enzyme 
revealed by molecular cloning. Proc Natl Acad Sci U S A. 85, 9386-9390 
21 
 
3 Erdos, E. G. (1990) Angiotensin I converting enzyme and the changes in our concepts 
through the years. Lewis K. Dahl memorial lecture. Hypertension. 16, 363-370 
4 Skidgel, R. A. and Erdos, E. G. (1985) Novel activity of human angiotensin I converting 
enzyme: release of the NH2- and COOH-terminal tripeptides from the luteinizing hormone-
releasing hormone. Proc Natl Acad Sci U S A. 82, 1025-1029 
5 Rousseau, A., Michaud, A., Chauvet, M. T., Lenfant, M. and Corvol, P. (1995) The 
hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-
terminal active site of human angiotensin-converting enzyme. J Biol Chem. 270, 3656-3661 
6 Oba, R., Igarashi, A., Kamata, M., Nagata, K., Takano, S. and Nakagawa, H. (2005) The 
N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer 
amyloid beta-peptide. Eur J Neurosci. 21, 733-740 
7 Zou, K., Maeda, T., Watanabe, A., Liu, J., Liu, S., Oba, R., Satoh, Y., Komano, H. and 
Michikawa, M. (2009) Abeta42-to-Abeta40- and angiotensin-converting activities in different 
domains of angiotensin-converting enzyme. J Biol Chem. 284, 31914-31920 
8 Fuchs, S., Xiao, H. D., Hubert, C., Michaud, A., Campbell, D. J., Adams, J. W., 
Capecchi, M. R., Corvol, P. and Bernstein, K. E. (2008) Angiotensin-converting enzyme C-
terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension. 51, 
267-274 
9 Wei, L., Alhenc-Gelas, F., Corvol, P. and Clauser, E. (1991) The two homologous 
domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem. 
266, 9002-9008 
10 Fuchs, S., Xiao, H. D., Cole, J. M., Adams, J. W., Frenzel, K., Michaud, A., Zhao, H., 
Keshelava, G., Capecchi, M. R., Corvol, P. and Bernstein, K. E. (2004) Role of the N-terminal 
catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in 
mice. J Biol Chem. 279, 15946-15953 
11 Jaspard, E., Wei, L. and Alhenc-Gelas, F. (1993) Differences in the properties and 
enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). 
Studies with bradykinin and other natural peptides. J Biol Chem. 268, 9496-9503 
12 Rasoul, S., Carretero, O. A., Peng, H., Cavasin, M. A., Zhuo, J., Sanchez-Mendoza, A., 
Brigstock, D. R. and Rhaleb, N. E. (2004) Antifibrotic effect of Ac-SDKP and angiotensin-
converting enzyme inhibition in hypertension. J Hypertens. 22, 593-603 
22 
 
13 Xu, H., Yang, F., Sun, Y., Yuan, Y., Cheng, H., Wei, Z., Li, S., Cheng, T., Brann, D. and 
Wang, R. (2012) A new antifibrotic target of Ac-SDKP: inhibition of myofibroblast 
differentiation in rat lung with silicosis. PLoS One. 7, e40301 
14 Bernstein, K. E., Khan, Z., Giani, J. F., Cao, D. Y., Bernstein, E. A. and Shen, X. Z. 
(2018) Angiotensin-converting enzyme in innate and adaptive immunity. Nat Rev Nephrol. 14, 
325-336 
15 Cao, D. Y., Spivia, W. R., Veiras, L. C., Khan, Z., Peng, Z., Jones, A. E., Bernstein, E. 
A., Saito, S., Okwan-Duodu, D., Parker, S. J., Giani, J. F., Divakaruni, A. S., Van Eyk, J. E. 
and Bernstein, K. E. (2020) ACE overexpression in myeloid cells increases oxidative 
metabolism and cellular ATP. J Biol Chem. 295, 1369-1384 
16 Khan, Z., Cao, D. Y., Giani, J. F., Bernstein, E. A., Veiras, L. C., Fuchs, S., Wang, Y., 
Peng, Z., Kalkum, M., Liu, G. Y. and Bernstein, K. E. (2019) Overexpression of the C-domain 
of angiotensin-converting enzyme reduces melanoma growth by stimulating M1 macrophage 
polarization. J Biol Chem. 294, 4368-4380 
17 Dive, V., Cotton, J., Yiotakis, A., Michaud, A., Vassiliou, S., Jiracek, J., Vazeux, G., 
Chauvet, M. T., Cuniasse, P. and Corvol, P. (1999) RXP 407, a phosphinic peptide, is a potent 
inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. 
Proc Natl Acad Sci U S A. 96, 4330-4335 
18 Douglas, R. G., Sharma, R. K., Masuyer, G., Lubbe, L., Zamora, I., Acharya, K. R., 
Chibale, K. and Sturrock, E. D. (2014) Fragment-based design for the development of N-
domain-selective angiotensin-1-converting enzyme inhibitors. Clin Sci (Lond). 126, 305-313 
19 Otvos, L., Jr. and Wade, J. D. (2014) Current challenges in peptide-based drug discovery. 
Front Chem. 2, 62 
20 Kroger, W. L., Douglas, R. G., O'Neill, H. G., Dive, V. and Sturrock, E. D. (2009) 
Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in 
angiotensin-converting enzyme. Biochemistry. 48, 8405-8412 
21 Watermeyer, J. M., Sewell, B. T., Schwager, S. L., Natesh, R., Corradi, H. R., Acharya, 
K. R. and Sturrock, E. D. (2006) Structure of testis ACE glycosylation mutants and evidence 
for conserved domain movement. Biochemistry. 45, 12654-12663 
22 Yates, C. J., Masuyer, G., Schwager, S. L., Akif, M., Sturrock, E. D. and Acharya, K. R. 
(2014) Molecular and thermodynamic mechanisms of the chloride-dependent human 
angiotensin-I-converting enzyme (ACE). J Biol Chem. 289, 1798-1814 
23 
 
23 Lubbe, L., Sewell, B. T. and Sturrock, E. D. (2016) The influence of angiotensin 
converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition. 
FEBS J. 283, 3941-3961 
24 Sharma, R. K., Douglas, R. G., Louw, S., Chibale, K. and Sturrock, E. D. (2012) New 
ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-
domain selective inhibition of angiotensin-converting enzyme. Biol Chem. 393, 485-493 
25 Fienberg, S., Cozier, G. E., Acharya, K. R., Chibale, K. and Sturrock, E. D. (2018) The 
design and development of a potent and selective novel diprolyl derivative that binds to the N-
domain of angiotensin-I converting enzyme. J Med Chem. 61, 344-359 
26 Bull, H. G., Thornberry, N. A. and Cordes, E. H. (1985) Purification of angiotensin-
converting enzyme from rabbit lung and human plasma by affinity chromatography. J Biol 
Chem. 260, 2963-2972 
27 Cozier, G. E., Arendse, L. B., Schwager, S. L., Sturrock, E. D. and Acharya, K. R. (2018) 
Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain: 
Implications for Drug Design. J Med Chem. 61, 10141-10154 
28 Carmona, A. K., Schwager, S. L., Juliano, M. A., Juliano, L. and Sturrock, E. D. (2006) 
A continuous fluorescence resonance energy transfer angiotensin I-converting enzyme assay. 
Nat Protoc. 1, 1971-1976 
29 Cheng, Y. and Prusoff, W. H. (1973) Relationship between the inhibition constant (K1) 
and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic 
reaction. Biochem Pharmacol. 22, 3099-3108 
30 Anthony, C. S., Corradi, H. R., Schwager, S. L., Redelinghuys, P., Georgiadis, D., Dive, 
V., Acharya, K. R. and Sturrock, E. D. (2010) The N domain of human angiotensin-I-
converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N 
domain-specific phosphinic inhibitor, RXP407. J Biol Chem. 285, 35685-35693 
31 Redelinghuys, P., Nchinda, A. T., Chibale, K. and Sturrock, E. D. (2006) Novel 
ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular 
modelling. Biol Chem. 387, 461-466 
32 Waterman, D. G., Winter, G., Gildea, R. J., Parkhurst, J. M., Brewster, A. S., Sauter, N. 
K. and Evans, G. (2016) Diffraction-geometry refinement in the DIALS framework. Acta 
Crystallogr D Struct Biol. 72, 558-575 
24 
 
33 Evans, P. R. and Murshudov, G. N. (2013) How good are my data and what is the 
resolution? Acta Crystallogr D Biol Crystallogr. 69, 1204-1214 
34 Collaborative Computational Project Number 4. (1994) The CCP4 suite: programs for 
protein crystallography. Acta Crystallogr D Biol Crystallogr. 50, 760-763 
35 McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. and 
Read, R. J. (2007) Phaser crystallographic software. J Appl Crystallogr. 40, 658-674 
36 Cozier, G. E., Schwager, S. L., Sharma, R. K., Chibale, K., Sturrock, E. D. and Acharya, 
K. R. (2018) Crystal structures of sampatrilat and sampatrilat-Asp in complex with human 
ACE - a molecular basis for domain selectivity. FEBS J. 285, 1477-1490 
37 Murshudov, G. N., Vagin, A. A. and Dodson, E. J. (1997) Refinement of macromolecular 
structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 53, 240-
255 
38 Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, 
J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., 
Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C. and Zwart, P. 
H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure 
solution. Acta Crystallogr D Biol Crystallogr. 66, 213-221 
39 Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. 
Acta Crystallogr D Biol Crystallogr. 60, 2126-2132 
40 Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, 
G. J., Murray, L. W., Richardson, J. S. and Richardson, D. C. (2010) MolProbity: all-atom 
structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 
66, 12-21 
41 McNicholas, S., Potterton, E., Wilson, K. S. and Noble, M. E. (2011) Presenting your 
structures: the CCP4mg molecular-graphics software. Acta Crystallogr D Biol Crystallogr. 67, 
386-394 
42 Laskowski, R. A. and Swindells, M. B. (2011) LigPlot+: multiple ligand-protein 
interaction diagrams for drug discovery. J Chem Inf Model. 51, 2778-2786 
43 Natesh, R., Schwager, S. L., Sturrock, E. D. and Acharya, K. R. (2003) Crystal structure 
of the human angiotensin-converting enzyme-lisinopril complex. Nature. 421, 551-554 
44 Redelinghuys, P., Nchinda, A. T. and Sturrock, E. D. (2005) Development of domain-
selective angiotensin I-converting enzyme inhibitors. Ann N Y Acad Sci. 1056, 160-175 
25 
 
45 Natesh, R., Schwager, S. L. U., Evans, H. R., Sturrock, E. D. and Acharya, K. R. (2004) 
Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human 
testicular angiotensin I-converting enzyme. Biochemistry. 43, 8718-8724 
 
  
26 
 
Table 1. Catalytic efficiency of Abz-FRK(Dnp)P-OH hydrolysis by wild-type and mutant 
proteins. Initial reaction velocities (<10% of substrate hydrolysis) were analysed using the 
Michaelis Menten model in GraphPad Prism® v6.01 for determination of Km and kcat values 
(represented as mean ± SD of three independent experiments). 
 
Construct Km (μM) kcat (s-1) kcat/Km(s-1. μM-1) 
nACE 7.54 ± 1.7 1.9 ± 0.3 0.26 ± 0.04 
S′-nACE 4.51 ± 2.0 1.2 ± 0.5 0.27 ± 0.03 
S2-nACE  11.92 ± 1.0 4.5 ± 1.4 0.38 ± 0.14 
S2_S′-nACE 12.40 ± 1.6 6.0 ± 0.7 0.48 ± 0.03 
cACE 6.30 ± 1.1 2.6 ± 0.5 0.42 ± 0.05 
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Table 2. Affinity of inhibitor binding to the wild-type and mutant proteins. Inhibitor binding 
constants (Ki values) were determined from inhibition assays via Morrison plots and are 
represented as mean ± SD of at least two independent experiments. For SG6, enalaprilat and 
omapatrilat Ki 
app was equal to Ki due to the tight-binding nature of inhibition whereas Ki values 
for ketoACE13 were calculated from Ki 
app values using the Cheng-Prusoff equation (Cheng 
and Prusoff, 1973). 
 
Inhibitors Proteins Ki (nM) Selectivity 
(Ki cACE / Ki nACE or mutant)  
33RE* 
nACE 11.21 ± 0.735 1006 
S′-nACE 237.22 ± 13.60 48 
S2-nACE 2 794 ± 156 4 
S2_S′-nACE 10 009 ± 157 1.1 
cACE 11 278 ± 410 1 
SG6 
nACE 0.093 ± 0.02 825 
S′-nACE 1.09 ± 0.1 70 
S2-nACE 44.05 ± 2.8 1.7 
S2_S′-nACE 72.93 ± 7.5 1.1 
cACE 76.77 ± 4.3 1 
KetoACE13 
nACE 1 000 ± 270 8 
S′-nACE 2 990 ± 1 000 3 
S2-nACE 17 810 ± 1 100 0.5 
S2_S′-nACE 47 750 ± 13 600 0.2 
cACE 8 250 ± 430 1 
Enalaprilat 
nACE 0.75 ± 0.20 0.2 
S′-nACE  1.85 ± 0.21 0.09 
 S2-nACE 1.56 ± 0.41 0.1 
 S2_S′-nACE 3.00 ± 0.24 0.05 
 cACE 0.16 ± 0.01 1 
Omapatrilat 
nACE 0.37 ± 0.05 2 
S′-nACE  0.49 ± 0.04 1 
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 S2-nACE 0.43 ± 0.13 2 
 S2_S′-nACE 0.29 ± 0.01 2 
 cACE 0.70 ± 0.09 1 
* Lubbe et al., 2016 
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Table 3. X-ray data collection and refinement statistics. Inner shell, overall and outer shell 
statistics are given in square brackets, un-bracketed and round brackets respectively. 
 
 33RE SG6 Omapatrilat 
Resolution (Å) 
[74.14-9.86]
(1.83-1.80)
[75.11-9.31]
(1.73-1.70)
[64.01-9.86] 
(1.83-1.80) 
Space group P1 P1 P1 
Cell dimensions (a,b,c) 
angles (α,β,γ)
73.2, 77.1, 82.9 Å
88.9, 64.5, 75.2°
73.6, 78.2, 83.8 Å
88.6, 64.4, 74.6°
74.4, 78.8, 89.7 Å 
92.4, 106.0, 114.6° 
Molecules/asymmetric 
unit 
2 2 2 
Total / Unique reflections  980,600/141,976 1,188,881/172,853 1,093,096/157,824 
Completeness (%) [99.3] 97.4 (96.2) [99.4] 97.2 (95.4) [99.3] 97.2 (96.1) 
Rmerge
 [0.041] 0.083 (0.923) [0.021] 0.084 (0.836) [0.017] 0.069 (0.692) 
Rpim [0.016] 0.034 (0.371) [0.008] 0.034 (0.372) [0.007] 0.028 (0.291) 
<I/σ(I)> [42.7] 11.5 (1.9) [65.9] 11.6 (1.6) [66.8] 13.9 (2.0) 
CC1/2
 [0.999] 0.999 (0.652) [1.000] 0.999 (0.511) [1.000] 0.999 (0.776) 
Multiplicity [7.1] 6.9 (7.1) [7.8] 6.9 (6.0) [7.8] 6.9 (6.5) 
Refinement statistics 
Rwork/Rfree
 0.200/0.237 0.188/0.221 0.182/0.222 
Rmsd in bond lengths (Å) 0.010 0.009 0.010 
Rmsd in bond angles (°) 1.076 0.967 1.011 
Ramachandran statistics (%) 
Favoured 97.0 97.9 98.2 
Allowed 2.8 2.1 1.7 
Outliers 0.2 0.0 0.1 
Average B- factors (Å2) 
Protein 38.62 34.50 36.02 
Ligand 46.29 48.06 55.15 
Water 37.64 37.86 39.05 
Number of atoms 
Protein 9836 9963 10088 
Ligand 337 375 395 
Water 795 888 989 
PDB code 6TT1 6TT3 6TT4 
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Table 4. Comparison of the overall structures of N389-S2_S′-nACE inhibitor complexes and 
N389-nACE. RMSD values (Å) for 602 Cα atoms observed in all structures. Values were 
generated using the ‘Structure Alignment and Superposition with Gesamt‘ program on CCP4 
cloud. 
 
 
N389-S2_S′-nACE 
33RE Omapatrilat SG6 
N389-nACE 0.43 0.48 0.48 
N389-S2_S′-nACE 
33RE - 0.47 0.34 
Omapatrilat - - 0.52 
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Figure 1. Chemical structures of the ACE inhibitors studied here. Inhibitor moieties are 
annotated with Schechter-Berger nomenclature based on their interactions with the non-prime 
and prime subsites flanking the active site Zn2+. 
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Figure 2: Effect of mutation on N-selective inhibition, integrity of omapatrilat at ambient 
temperature as monitored by HPLC and SDS-PAGE gel illustrating decreased molecular 
weight of the active site mutant N389-S2_S′-nACE. A) Inhibitor binding affinities (Ki values) 
for wild-type cACE or nACE mutants are shown on a log scale relative to nACE with error 
bars representing mean ± SD of at least two independent experiments.  B) Omapatrilat (50μM 
in assay buffer) was analysed using a Poroshell 120 EC-C 18 column on the Agilent 1260 
infinity HPLC system. Twenty microliters of sample was injected onto the column immediately 
after preparation or following incubation at ambient temperature for 1, 2 or 3 hours. Conditions: 
A: 1% ACN, 0.1% TFA; B: 95% ACN, 0.1% TFA; 0- 100% B over 10 min; 0.5 mL/min, 214 
nm. Peaks corresponding to the monomer and dimer were observed at 7.99 and 9.34 minutes, 
respectively.  C)  SDS-PAGE of purified nACE proteins 1) Fully glycosylated S2_S′-nACE, 2) 
minimally glycosylated N389-nACE and 3) minimally glycosylated N389-S2_S′-nACE. 
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Figure 3. Schematic representation of the overall structures of N389-nACE and N389-
S2_S′-nACE/inhibitor complexes. A) Wild-type N389-nACE, B) N389-S2_S′-nACE/33RE 
complex, C) N389-S2_S′-nACE/SG6 complex and D) N389-S2_S′-nACE/omapatrilat 
complex. 33RE, SG6 and omapatrilat inhibitors are shown as magenta, orange and olive sticks 
respectively. Zinc and chloride ions are depicted as lilac and green spheres respectively, with 
helices, β-strands and loops coloured in rose, dark cyan and tan respectively. 
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Figure 4. N389-S2-S′-nACE structures confirm the presence of the mutations. The final 
2mFo – DFc (blue, contoured at 1σ level) and the omit mFo – DFc (green, contoured at 3σ 
level) electron density maps for the N389-S2_S′-nACE/SG6 structure clearly show the eight 
mutations, which are depicted as sticks with α-Helices, β-strands and loops shown in rose, dark 
cyan and tan respectively.  
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Figure 5. Inhibitors bound to N389-S2_S′-nACE. A) 33RE, B) SG6 and C) Omapatrilat 
shown as schematic representations bound to N389-S2_S′-nACE with the final 2mFo – DFc 
(blue, contoured at 1σ level) and the omit mFo – DFc (green, contoured at 3σ level) electron 
density maps. Zinc ions are depicted as lilac spheres with the coordinating side chains shown 
as sticks (Glu389 is obscured in this view, so not labelled). α-Helices and β-strands are shown 
in rose and dark cyan, respectively. Overlays are shown of D) 33RE, E) SG6 and F) Omapatrilat 
bound to wild-type N389-nACE and N389-S2_S′-nACE. The inhibitors from wild-type 
structures are coloured dark magenta for 33RE (PDB 4BXK), orange red for SG6 (PDB 6EN5) 
and dark olive for omapatrilat (PDB 6H5X), with the zinc ions as dark lilac spheres. N389-
S2_S′-nACE bound inhibitors are coloured magenta, orange and olive for 33RE, SG6 and 
omapatrilat respectively, with lilac sphere zinc ions. 
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Figure 6. Ligplot representations of inhibitor binding interactions. Comparison of A) 33RE, 
B) SG6 and C) Omapatrilat bound to N389-S2_S′-nACE, with D) 33RE (PDB 4BXK), E) SG6 
(PDB 6EN5) and F) Omapatrilat (PDB 6H5X) wild-type N389-nACE complexes. H-
bond/electrostatic and hydrophobic interactions are shown as green and red dashed lines 
respectively, water molecules as cyan spheres, and red, semi-circular symbols depict residues 
solely involved in hydrophobic interactions. 
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Figure 7. Overlay of N389-S2_S′-nACE mutations with wild-type N389-nACE. Inhibitor 
complexes with N389-S2_S′-nACE (33RE in magenta, SG6 in orange and omapatrilat in olive) 
and wild-type N389-nACE (33RE in dark magenta (PDB 4BXK), SG6 in orange red (PDB 
6EN5) and omapatrilat in dark olive (PDB 6H5X)) are overlaid with close up views of (A-C) 
Non-prime, (D-F) S1′ and (G-I) distal S′ mutations.  
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Figure 8. Interactions of mutated residues near predicted hinge region. Close up view of 
the S′ residues included in the N389-S2_S′-nACE mutations showing their interactions in A) 
Wild-type N389-nACE and B) N389-S2_S′-nACE/SG6 structures. The two sub-domains are 
coloured light blue and dark cyan. Water molecules and magnesium ion are shown as red and 
green spheres respectively. 
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Figure 9. Binding of enalaprilat to cACE. Enalaprilat is shown as green sticks bound to 
cACE (light green ribbon, PDB ID 1UZE), the zinc ion as a grey sphere and the unique S2 and 
distal prime subsite residues as green wires. The unique cACE residues E143 and S516 interact 
to potentially stabilize a loop region highlighted in yellow (harbouring the unique V518) and 
increase the strength of enalaprilat interaction with the conserved residues (yellow sticks). 
 
